US regulatory status: approved. Molecular target: Maltase-glucoamylase.
- Target
- Maltase-glucoamylase
- Mechanism
- Pancreatic alpha-amylase inhibitor
pharma · PCOS · Stomach Neoplasms
Renji Hospital
RenJi Hospital
Renji Hospital drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shanghai, CN HQ
608 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 608
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Renji Hospital pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Renji Hospital drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
fruquintinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Renji Hospital in public FDA and regional records.